Feb 11 (Reuters) - Sellas Life Sciences Group Inc:
* SELLAS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 1 TRIAL OF GALINPEPIMUT-S (GPS) IN COMBINATION WITH NIVOLUMAB (OPDIVO®) IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.